306 320
Drafting of the manuscript:
Gershman, Lohse, Leibovich.
Critical revision of the manuscript for important intellectual content:
Gershman, Thompson, Moreira, Boorjian, Lohse, Costello, Cheville,
Leibovich.
Statistical analysis:
Lohse.
Obtaining funding:
None.
Administrative, technical, or material support:
None.
Supervision:
Thompson, Leibovich.
Other:
None.
Financial disclosures:
Boris Gershman certifies that all conflicts of
interest, including specific financial interests and relationships and
affiliations relevant to the subject matter or materials discussed in the
manuscript (eg, employment/affiliation, grants or funding, consultan-
cies, honoraria, stock ownership or options, expert testimony, royalties,
or patents filed, received, or pending), are the following: None.
Funding/Support and role of the sponsor:
None.
Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at
http://dx.doi.org/10.1016/j. eururo.2016.12.027.
References
[1]
Margulis V, Wood CG. The role of lymph node dissection in renal cell carcinoma: the pendulum swings back. Cancer J 2008;14:308–14.[2]
Leibovich BC, Blute ML. Lymph node dissection in the management of renal cell carcinoma. Urol Clin North Am 2008;35:673–8.[3]
Capitanio U, Becker F, Blute ML, et al. Lymph node dissection in renal cell carcinoma. Eur Urol 2011;60:1212–20.[4]
Pantuck AJ, Zisman A, Dorey F, et al. Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J Urol 2003;169:2076–83.[5]
Vasselli JR, Yang JC, LinehanWM, White DE, Rosenberg SA, Walther MM. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. J Urol 2001;166: 68–72.[6]
Whitson JM, Harris CR, Reese AC, Meng MV. Lymphadenectomy improves survival of patients with renal cell carcinoma and nodal metastases. J Urol 2011;185:1615–20.
[7]
Schafhauser W, Ebert A, Brod J, Petsch S, Schrott KM. Lymph node involvement in renal cell carcinoma and survival chance by sys- tematic lymphadenectomy. Anticancer Res 1999;19:1573–8.[8]
Capitanio U, Suardi N, Matloob R, et al. Extent of lymph node dissection at nephrectomy affects cancer-specific survival and metastatic progression in specific sub-categories of patients with renal cell carcinoma (RCC). BJU Int 2014;114:210–5.[9]
Blom JH, van Poppel H, Marechal JM, et al. Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) ran- domized phase 3 trial 30881. Eur Urol 2009;55:28–34.[10]
Feuerstein MA, Kent M, Bazzi WM, Bernstein M, Russo P. Analysis of lymph node dissection in patients with 7-cm renal tumors. World J Urol 2014;32:1531–6.
[11]
Sun M, Trinh QD, Bianchi M, et al. Extent of lymphadenectomy does not improve the survival of patients with renal cell carcinoma and nodal metastases: biases associated with the handling of missing data. BJU Int 2014;113:36–42.
[12]
Gershman B, Thompson RH, Moreira DM, et al. Radical nephrec- tomy with or without lymph node dissection for nonmetastatic renal cell carcinoma: a propensity score-based analysis. Eur Urol 2017;71:560–7.
[13]
Minervini A, Lilas L, Morelli G, et al. Regional lymph node dissection in the treatment of renal cell carcinoma: is it useful in patients with no suspected adenopathy before or during surgery? BJU Int 2001; 88:169–72.
[14]
Giuliani L, Giberti C, Martorana G, Rovida S. Radical extensive surgery for renal cell carcinoma: long-term results and prognostic factors. J Urol 1990;143:468–74.
[15]
Robson CJ, Churchill BM, Anderson W. The results of radical ne- phrectomy for renal cell carcinoma. J Urol 1969;101:297–301.[16]
Delacroix Jr SE, Chapin BF, Chen JJ, et al. Can a durable disease-free survival be achieved with surgical resection in patients with patho- logical node positive renal cell carcinoma? J Urol 2011;186:1236–41.
[17]
Canfield SE, Kamat AM, Sanchez-Ortiz RF, Detry M, Swanson DA, Wood CG. Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease (clinical stage TxN1-2M0): the impact of aggressive surgical resection on patient outcome. J Urol 2006;175:864–9.
[18]
Karakiewicz PI, Trinh QD, Bhojani N, et al. Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease: prognostic indicators of disease-specific survival. Eur Urol 2007; 51:1616–24.
[19]
Trinh QD, Schmitges J, Bianchi M, et al. Node-positive renal cell carcinoma in the absence of distant metastases: predictors of cancer-specific mortality in a population-based cohort. BJU Int 2012;110:E21–7.
[20]
Terrone C, Guercio S, De Luca S, et al. The number of lymph nodes examined and staging accuracy in renal cell carcinoma. BJU Int 2003;91:37–40.
[21]
Messing EM, Manola J, Wilding G, et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 2003;21:1214–22.
[22]
Pizzocaro G, Piva L, Colavita M, et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol 2001;19:425–31.
[23]
Hellsten S, Berge T, Linell F. Clinically unrecognised renal carcino- ma: aspects of tumor morphology, lymphatic and haematogenous metastatic spread. Br J Urol 1983;55:166–70.
[24]
Johnsen JA, Hellsten S. Lymphatogenous spread of renal cell carci- noma: an autopsy study. J Urol 1997;157:450–3.
[25]
Karmali RJ, Suami H, Wood CG, Karam JA. Lymphatic drainage in renal cell carcinoma: back to the basics. BJU Int 2014;114:806–17.
[26]
Baldewijns MM, Roskams T, Ballet V, et al. A low frequency of lymph node metastasis in clear-cell renal cell carcinoma is related to low lymphangiogenic activity. BJU Int 2009;103:1626–31.
[27]
Blute ML, Leibovich BC, Cheville JC, Lohse CM, Zincke H. A protocol for performing extended lymph node dissection using primary tumor pathological features for patients treated with radical nephrectomy for clear cell renal cell carcinoma. J Urol 2004;172:465–9.[28]
Capitanio U, Abdollah F, Matloob R, et al. When to perform lymph node dissection in patients with renal cell carcinoma: a novel approach to the preoperative assessment of risk of lymph node invasion at surgery and of lymph node progression during follow- up. BJU Int 2013;112:E59–66.
[29]
Babaian KN, Kim DY, Kenney PA, et al. Preoperative predictors of pathological lymph node metastasis in patients with renal cell carcinoma undergoing retroperitoneal lymph node dissection. J Urol 2014;193:1101–7.
[30]
Gershman B, Takahashi N, Moriera DM, et al. Radiographic size of retroperitoneal lymph nodes predicts pathologic nodal involve- ment for patients with renal cell carcinoma: development of a risk prediction model. BJU Int 2016;118:742–9.E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 3 0 0 – 3 0 6
306